Table 2.

Clinical course and comorbidities of the cohort (N=144).

	n (%) or mean (SD); median (IQR)
Treatment of ptosis and dysphagia
At least one blepharoptosis surgery	111 (77.1)
Age at first blepharoptosis surgery, y	60.0 (6.4); 59 (55–64)
Disease duration at first blepharoptosis surgery, y	6.8 (5.6); 5 (2–10)a
At least one procedure for dysphagia	57 (39.6)
Esophageal dilatation	47 (32.6)b
Cricopharyngeal botulinum toxin injection	25 (17.4)b
Cricopharyngeal myotomy	2 (1.4)
Age at first procedure for dysphagia, y	64.4 (8.7); 65 (58–70)
Disease duration at first procedure for dysphagia, y	11.1 (8.0); 9 (5–17)c
Markers of nutritional status
Gastrostomy	10 (6.9)
Age at gastrostomy, y	74.4 (9.6); 71 (67–84)
Disease duration at gastrostomy, y	18.9 (8.7); 21 (12.5–24.5)d
Body mass index, kg/m2	25.3 (4.6); 24.8 (22.4–28.2)e
Comorbidities
Functional Comorbidity Index	2.4 (1.9); 2 (1–3)
Peripheral neuropathy	8 (5.6)
Cognitive impairment	6 (4.2)f
Cardiac electrical disturbance	3 (2.1)
Cardiomyopathy	2 (1.4)
History of pneumonia	23 (16.0)
History of any cancer	21 (14.6)g

Abbreviations: SD = standard deviation; IQR = interquartile range

^aCalculated using n=107 due to 4 individuals who had blepharoptosis surgery but were missing age at earliest symptom.

^b1 individual underwent esophageal dilatation and cricopharyngeal botulinum toxin injection as a combined procedure.

^cCalculated using n=55 due to 2 individuals who underwent dysphagia procedures but were missing age at earliest symptom.

^dCalculated using n=8 due to 2 individuals who underwent gastrostomy but were missing age at earliest symptom.

^eThere were 27 missing observations (18.8%) for height.

^f5 individuals had adult-onset cognitive impairment not otherwise specified, and 1 had intellectual impairment.

^gCancer types included: breast (n=5), colon (n=4), prostate (n=4), lung (n=2), basal cell (n=2), Hodgkin’s lymphoma (n=1), acute promyelocytic leukemia (n=1), bladder (n=1), papillary thyroid (n=1), and endometrial (n=1).